FOR COPD
FOR ASTHMA
SYMBICORT 160/4.5 for the maintenance treatment of COPD
SYMBICORT is NOT a rescue medication and does NOT replace fast-acting inhalers to treat acute symptoms
†Sustained improvement in lung function was demonstrated in a 12-month efficacy and safety study.1,3
‡In a serial spirometry subset of patients taking SYMBICORT 160/4.5 (n=121) in the SUN Study, 67% of 1-hour postdose FEV1 improvement occurred at 5 minutes on day of randomization, 83% at month 6, and 84% at end of treatment.1-3
§Based on IMS data of new prescriptions (June 2016-March 2017).
The most common adverse reactions ≥3% reported in COPD clinical trials included nasopharyngitis, oral candidiasis, bronchitis, sinusitis, and upper respiratory tract infection.
SYMBICORT for your asthma patients ≥12 years of age uncontrolled on an ICS or whose disease severity clearly warrants an ICS/LABA
SYMBICORT is NOT a rescue medication and does NOT replace fast-acting inhalers to treat acute symptoms
†Sustained improvement in lung function was demonstrated in a 12-week efficacy and safety study.1,3
‡In patients taking SYMBICORT 160/4.5 (n=124) in Study 1, 79% of 2-hour postdose FEV1 improvement occurred at 15 minutes on day of randomization, 89% at week 2, and 90% at end of treatment.1-3
§Based on IMS data of new prescriptions (June 2016-March 2017).
The most common adverse reactions ≥3% reported in asthma clinical trials included nasopharyngitis, headache, upper respiratory tract infection, pharyngolaryngeal pain, sinusitis, influenza, back pain, nasal congestion, stomach discomfort, vomiting, and oral candidiasis.
SYMBICORT 160/4.5 for the maintenance treatment of COPD
SYMBICORT is NOT a rescue medication and does NOT replace fast-acting inhalers to treat acute symptoms
‡In a serial spirometry subset of patients taking SYMBICORT 160/4.5 (n=121) in the SUN Study, 67% of 1-hour postdose FEV1 improvement occurred at 5 minutes on day of randomization, 83% at month 6, and 84% at end of treatment.1-3
†Sustained improvement in lung function was demonstrated in a 12-month efficacy and safety study.1,3
The most common adverse reactions ≥3% reported in COPD clinical trials included nasopharyngitis, oral candidiasis, bronchitis, sinusitis, and upper respiratory tract infection.
Learn more about the safety and side effects of SYMBICORT 160/4.5 in COPD.
*Subject to eligibility rules; restrictions apply.
Learn more about the safety and side effects of SYMBICORT in asthma.
Looking for information on SYMBICORT for COPD?
*Subject to eligibility rules; restrictions apply.
